List of basic medicines: After preliminary selection, the catalogue includes 756 kinds of medicines, including 430 kinds of western medicines and 326 kinds of Chinese medicines; manufacturer's choice: take 3-5 years as a stage, and the province or city as a unit determines fixed-point manufacturers to purchase centrally; Mandatory provisions: Community health service centers (stations), township hospitals and other primary health care institutions should all be used, and other types of medical institutions should use it as the preferred drug and determine the proportion of use.
First, the number of drugs entering the catalog is greatly reduced. There are too many basic medicines, which is not conducive to doctors' rational use of medicines and basic medicines. The types of essential drugs recommended by the WTO to countries around the world and the practice of the international community show that there are about 200 to 300 basic drugs. China's most recent revised list of essential medicines contains 2,033 drugs, far exceeding the international level. The number of basic drug listings has been significantly reduced, and follow-up may be screened again, and the number is expected to decrease further.
Second, to promote the generalization of pharmaceutical production enterprises. The selection criteria for fixed-point manufacturers are not yet clarified, but due to the independent determination of manufacturers by provinces and municipalities, large-scale state-owned enterprises in the region are expected to benefit from the tilt of the policy as candidates; due to the principle of meagre pricing and government subsidies, fixed-point production enterprises may eventually It is to maintain a meager profit. Under such a background, the living environment of non-determined small-scale enterprises will deteriorate, and it can be expected that general pharmaceutical production enterprises will be concentrated and scaled.
Third, distribution companies will use this to establish a regional advantage. The state implements a "zero-judgment rate" policy, and destined for delivery will also be a meager profit. However, like the production companies, the most important thing is that the distribution companies can use this to achieve comprehensive coverage of provincial and municipal medical networks and establish an advantage within the region. It can be expected that once this distribution network is established, its low price and comprehensive coverage will exert tremendous pressure on competitors, which will undoubtedly have greater value for distribution companies.
Fourth, regional leading companies may be affected. In general, policies may centralize and scale the pharmaceutical industry and business in the region. Therefore, there are more opportunities for large-scale regional pharmaceutical and commercial companies. For these companies, short-term earnings are limited, and their value is more manifested after the scale of the company. Especially for commercial enterprises, the value of the network after the scale may be more obvious.
Leading industrial and commercial companies in all regions are worth paying attention to, raw materials and industrial enterprises, such as Qianjiang Biochemical, North China Pharmaceuticals, Baiyunshan, etc., and commercial enterprises such as Shanghai Pharmaceuticals, Accord Pharmaceutical, and East China Pharmaceutical.
First, the number of drugs entering the catalog is greatly reduced. There are too many basic medicines, which is not conducive to doctors' rational use of medicines and basic medicines. The types of essential drugs recommended by the WTO to countries around the world and the practice of the international community show that there are about 200 to 300 basic drugs. China's most recent revised list of essential medicines contains 2,033 drugs, far exceeding the international level. The number of basic drug listings has been significantly reduced, and follow-up may be screened again, and the number is expected to decrease further.
Second, to promote the generalization of pharmaceutical production enterprises. The selection criteria for fixed-point manufacturers are not yet clarified, but due to the independent determination of manufacturers by provinces and municipalities, large-scale state-owned enterprises in the region are expected to benefit from the tilt of the policy as candidates; due to the principle of meagre pricing and government subsidies, fixed-point production enterprises may eventually It is to maintain a meager profit. Under such a background, the living environment of non-determined small-scale enterprises will deteriorate, and it can be expected that general pharmaceutical production enterprises will be concentrated and scaled.
Third, distribution companies will use this to establish a regional advantage. The state implements a "zero-judgment rate" policy, and destined for delivery will also be a meager profit. However, like the production companies, the most important thing is that the distribution companies can use this to achieve comprehensive coverage of provincial and municipal medical networks and establish an advantage within the region. It can be expected that once this distribution network is established, its low price and comprehensive coverage will exert tremendous pressure on competitors, which will undoubtedly have greater value for distribution companies.
Fourth, regional leading companies may be affected. In general, policies may centralize and scale the pharmaceutical industry and business in the region. Therefore, there are more opportunities for large-scale regional pharmaceutical and commercial companies. For these companies, short-term earnings are limited, and their value is more manifested after the scale of the company. Especially for commercial enterprises, the value of the network after the scale may be more obvious.
Leading industrial and commercial companies in all regions are worth paying attention to, raw materials and industrial enterprises, such as Qianjiang Biochemical, North China Pharmaceuticals, Baiyunshan, etc., and commercial enterprises such as Shanghai Pharmaceuticals, Accord Pharmaceutical, and East China Pharmaceutical.
Phone case printer, also called uv led flatbed printer/UV Printer, belongs to Sapphire-Jet which is a multi functional LED UV Flatbed Printer that created by Shenzhen refinecolor technology co.,ltd. Phone case printer Printing on Glass Ceramic was built with industrial configuration as thicken aluminum profile, water cyculation cooling system, automatic detect UV Curing system... 6 color and max. 2880 dpi printing resolution. Can print on bend, cylinder objects, balls and bottles. Output with good 3D texture printing result.
Our phone case printer often using for phone case printing, It is easy for customizing printing and you can print any image in your computer with our printer.Customers can print their own photos, design and more from the photoshop or coreldraw software.
| Products name | Double XP600 Heads A3 Plus varnish Phone Case Printer A3 plus With Faster Speed |
| Model | RF-ZZ1/ZZ2 |
| UV lamp cooling system | Cycle water & air cooling + Heat sink |
| Printer head Protection | Intelligent Self Protect System |
| Printer Head | Double Printhead with XP600 (We also offer single printer) |
| 12 color printer(Ink support) | UV ink : CMYK+ 2gloss oil + 6 W |
| Ink system | Continue ink supply system with damper cartridge |
| Print Speed | 8 pass, 70s/A4 full size |
| Max Resolution | 16 pass |
| Max Printing Size | 330mm*600mm |
| Print Thickness | 0-200mm |
| Printer Size/packing size | 770mm*720mm*600mm / 98*83*78cm |
| Net/Gross/Volume weight | 52.5KG/88.5KG |
| UV lamp Temperature | 60 degree(UV lamp surface) |
|
|
|
| 40 degree (1cm far from lamp surface) | |
| Onekey to print aotumatically | Yes |
| Ink pump Automatically | Yes |
| Computer system | Windows system, Gigabit net, network adapter contain below character: Gigabit,GBE,10/100/1000M,RTL8169 |
| Standard Enclosure | Software 1 set, power line 1 set, Network line 1set, guidebook 1 set |
Phone Case Printer,Phone Case Digital Printer,Cell Phone Case Printer,Mobile Phone Case Printer,Phone Cell Printer
Shenzhen Refinecolor Technology Co., LTD. , https://www.szcakeprinter.com